Recruiting NA INTERVENTIONAL 2-arm NCT06014060

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial (DAPT-Lp(a))

Sponsor: China National Center for Cardiovascular Diseases

Conditions Coronary Artery Disease Drug-Eluting Stent Dual Antiplatelet Therapy Elevated Lipoprotein(a) Level

Interventions 12 Months DAPT 24 Months DAPT

Updated 5 times since 2023 Last updated: Jul 16, 2025 Started: Jun 20, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06014060, this NA trial focuses on Coronary Artery Disease and Drug-Eluting Stent and remains actively recruiting participants. Sponsored by China National Center for Cardiovascular Diseases, it has been updated 5 times since 2025, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Aug 2025 — Present [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting NA
Sep 2024 — Jul 2025 [monthly]

Not Yet Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Sep 2023 — Jul 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China National Center for Cardiovascular Diseases

Data source: China National Center for Cardiovascular Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China